Skip to main content

Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Publication ,  Other
Patel, R; Saab, K; Luo, L; Ma, Y; Osman, RA; Williams, NT; Everitt, J; Zelazowski, MJ; Castro, P; Decker, WK; Hudson, WH; Myers, JN ...
October 1, 2025

<p>TP53 GOF defined using the IARC database</p>

Duke Scholars

DOI

Publication Date

October 1, 2025
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, R., Saab, K., Luo, L., Ma, Y., Osman, R. A., Williams, N. T., … Kirsch, D. G. (2025). Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. https://doi.org/10.1158/1078-0432.30254936
Patel, Rutulkumar, Kalil Saab, Lixia Luo, Yan Ma, Rashid Abdullah Osman, Nerissa T. Williams, Jeffrey Everitt, et al. “Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma,” October 1, 2025. https://doi.org/10.1158/1078-0432.30254936.
Patel R, Saab K, Luo L, Ma Y, Osman RA, Williams NT, Everitt J, Zelazowski MJ, Castro P, Decker WK, Hudson WH, Myers JN, Sandulache VC, Frederick MJ, Mowery YM, Kirsch DG. Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. 2025.

DOI

Publication Date

October 1, 2025